Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

With major drugs like Entresto, Promacta, and Tasigna facing generic competition in 2025, Novartis could experience a substantial erosion of its revenue base. These products have been important ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Swiss pharmaceutical company Novartis envisions a world where access to healthcare is not a privilege but a fundamental human right, and this vision drives its global health initiatives.

we assume a more than 50% probability of Novartis seeing future costs related to product governance ESG risks (such as off-label marketing or litigation related to side effects) and model base ...